Alpha-1 15%
- Generic Name
- Alpha-1 15%
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants with Alpha1-Antitrypsin Deficiency
Phase 1
Active, not recruiting
- Conditions
- Alpha1-Antitrypsin Deficiency
- Interventions
- Biological: Liquid Alpha1-Proteinase Inhibitor (Human)
- First Posted Date
- 2021-01-25
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 16
- Registration Number
- NCT04722887
- Locations
- 🇺🇸
Dignity Health-St. Joseph's Hospital & Medical Center, Phoenix, Arizona, United States
🇺🇸UCLA Medical Center, Los Angeles, California, United States
🇺🇸University of Florida, Gainesville, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath